Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal

@article{Lhermite2017BioidenticalMH,
  title={Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal},
  author={Marc L'hermite},
  journal={Climacteric},
  year={2017},
  volume={20},
  pages={331 - 338}
}
Abstract The many advantages of registered bioidentical sex hormones over registered, conventional, non-bioidentical menopausal hormone therapy (MHT) are considered. The transdermal route of estrogen administration avoids excess venous thromboembolic and ischemic stroke events. There is some indication that conjugated equine estrogens are more thrombogenic and most likely induce some hypertensive responses; estradiol might also be superior to conjugated equine estrogens (CEE) in terms of global… Expand
Choice of progestogen for endometrial protection in combination with transdermal estradiol in menopausal women
  • A. Mueck, T. Römer
  • Medicine, Biology
  • Hormone molecular biology and clinical investigation
  • 2018
TLDR
The aim of this review was to summarize data on the endometrial effects of the different progestogens and to provide practical recommendations for the choice of progestogen (type and dosing), with a focus onendometrial protection when using TE, especially when using the novel estradiol (E2) spray. Expand
Will estradiol/progesterone capsules for oral use become the best choice for menopausal hormone therapy?
  • A. Mueck, X. Ruan
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2019
TLDR
The cardiometabolic parameters assessed in the REPLENISH study are laboratory parameters commonly used for screening purposes in internal medicine and thus it can be concluded that E2/P4 combinations, used orally in postmenopausal women in good cardiovascular health, are neutral with respect to lipid and glucose metabolism and within the coagulation system. Expand
The Clinical Utility of Compounded Bioidentical Hormone Therapy
TLDR
Whether the available evidence suggests that these preparations have clinical utility and safety profiles warranting their clinical use and identifies patient populations that might benefit from cBHT preparations in lieu of FDA-approved BHT is assessed. Expand
The history of natural progesterone, the never-ending story
  • P. Piette
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2018
TLDR
Progesterone provides adequate endometrial protection and is suggested to be the optimal progestagen in menopausal hormone therapy in terms of cardiovascular effects, venous thromboembolism, probably stroke and even breast cancer risk. Expand
Changes in breast density during hormone treatment with transdermal estrogens alone or in combination with progesterone
TLDR
No increased breast density was observed in women on HT treatment, nor did the authors observe an increase according to HT type, but the difference in breast density loss was smaller in the HT group versus the control group. Expand
Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study
TLDR
The findings support a protective effect of estrogen on CO VID-19, based on positive association between predicted COVID-19 and menopausal status, and a negative association with COCP use. Expand
Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study
  • R. Costeira, Karla A Lee, +14 authors Jordana T Bell
  • Medicine
  • PloS one
  • 2021
TLDR
A protective effect of estrogen exposure on CO VID-19 is supported, based on positive association between predicted COVID-19 with menopausal status, and negative association with COCP use. Expand
Progesterone: History, facts, and artifacts.
Progesterone and its related molecules are a crucial tool in modern clinical practice, particularly in the fields of reproductive medicine. Its history is old, but still under development. Presently,Expand
Current trends in the hormone replacement therapy
TLDR
Hormonální substituční terapie byla v posledních desetiletích často diskutovaným tématem ke stabilizaci názorů na vhodnost použití, indikace a kontraindikace této léčby. Expand
Exogenous progestogens differentially alter gene expression of immature cumulus-oocyte complexes in sheep.
TLDR
P4 and MAP promoted dissimilar effects on transcriptome profiling of immature BCB-selected COCs, possibly due to the differences in the chemical structure of progestogens and concentrations of serum P4. Expand
...
1
2
...

References

SHOWING 1-10 OF 85 REFERENCES
HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT
  • M. L'hermite
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2013
TLDR
Natural, ‘body-identical’ progesterone appears to be the optimal progestogen in terms of cardiovascular effects, blood pressure, VTE, probably stroke and even breast cancer (contrary to synthetic progestogens and particularly MPA, which appear to be mitogenic on breast cells, in synergism with estrogen). Expand
Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
TLDR
While all types of hormone replacement therapies are safe and effective and confer significant benefits in the long-term when initiated in young postmenopausal women, in specific clinical settings the choice of the transdermal route of administration of estrogens and the use of natural progesterone might offer significant benefits and added safety. Expand
Pharmacology of conjugated equine estrogens: Efficacy, safety and mechanism of action
TLDR
Selective combinations of ring B unsaturated estrogens have the potential of being developed as novel therapeutic agents for the prevention of cardiovascular disease and Alzheimer's disease in both aging women and men. Expand
New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation
  • R. Sitruk-Ware
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2007
TLDR
The combination of non-oral administration of estradiol and local delivery of progesterone or a progestin such as levonorgestrel by means of gels, sprays, vaginal rings or intrauterine systems would represent new methods of replacement therapy for the menopausal woman, improving compliance and minimizing the risks of hormone replacement. Expand
Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study
TLDR
Oral estrogen therapy increases venous thromboembolism risk among postmenopausal women using hormone therapy and route of estrogen administration and concomitant progestogens type are 2 important determinants of thrombotic risk. Expand
Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens.
TLDR
In an observational study of oral hormone therapy users, CEEs use was associated with a higher risk of incident venous thrombosis and possibly myocardial infarction than estradiol use, and various oral estrogen drugs may be associated with different levels of cardiovascular risk. Expand
Oral versus transdermal estrogens and venous thromboembolism in postmenopausal women: what is new since 2003?
TLDR
A recent meta-analysis has confirmed the advantage of transdermal versus oral estrogens regarding VTE risk, despite divergences in rating the quality of evidence in this issue of Menopause. Expand
What if the Women’s Health Initiative had used transdermal estradiol and oral progesterone instead?
TLDR
The author uses statistical methods to ascertain the attributable risk of venous thromboembolism for transdermal estradiol versus oral hormone therapy and imputes those risks into the WHI primary outcomes. Expand
Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.
TLDR
Oral estradiol therapy was associated with less progression of subclinical atherosclerosis (measured as CIMT) than was placebo when therapy was initiated within 6 years after menopause but not when it was initiated 10 or more years afterMenopause. Expand
Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes.
TLDR
OC and HT can safely be used for contraception and treatment of vasomotor symptoms, respectively, by healthy women at low baseline risk for cardiovascular disease and breast cancer, and subgroup analyses suggest that timing of HT initiation influences the relation between such therapy and coronary risk. Expand
...
1
2
3
4
5
...